BCL2 and diffuse large B-cell lymphoma: In the present study we demonstrate that the poor prognosis of DLBCL patients overexpressing BCL-2 is due only in part to the direct antiapoptotic activity mediated by BCL-2, but it is in fact also the consequence of reduced p53 activation upon exposure to chemotherapeutic agents inhibiting ribosome biogenesis, such as anthracyclines.